The isolation of Burkholderia cepacia complex organisms can have a devastating effect on many patients with cystic fibrosis (CF) and is often the most difficult event to occur in their lives. Infection results in strict segregation, reduced likelihood of transplantation and is associated with both increased morbidity and mortality.
Although the prevalence of B. cepacia complex is relatively low at around 5% in most countries, in centres where there have been significant outbreaks of this infection, the prevalence can be as high as 25%. 1, 2 Thankfully, with strict infection control measures, cross infection has been reduced to a minimum and the incidence of new infection with this organism is less than 1% even in those centres with a relatively high prevalence. 3, 4 The clear taxonomy of species within the Burkholderia cepacia complex has greatly helped understanding the epidemiology of this organism. Some of the historical data is difficult to interpret as the organism has been previously called Pseudomonas cepacia. Until a few years ago B. cepacia complex infection was reported as being a single organism, then as genomovars and more recently as Burkholderia species with B. cenocepacia and B. multivorans being the most common.
Burkholderia cenocepacia is the most common organism in this group in the UK, mainland Europe and Canada whereas in North America and Australia seem to have a higher prevalence of B. multivorans and other members of the complex. [5] [6] [7] [8] [9] [10] [11] B. cenocepacia and B. multivorans are the most common members of the complex isolated worldwide and differences are emerging with regard to the clinical course of patients infected with these two organisms.
Identification of B. cepacia complex
Making a correct diagnosis from sputum culture is critical in managing patients with B. cepacia complex infection. Appropriate media needs to be used to culture the organism and commercial test kits such as API20NE are useful but have a significant false positives. 12, 13 Stenotrophomonas maltophilia, Achromobacter xyloxidans and occasionally P. aeruginosa can both be erroneously diagnosed as B. cepacia complex organisms. 13 As these organisms have a more benign effect on pulmonary function compared to B. cepacia complex, an incorrect diagnosis may result in patients being inappropriately cohorted with those who are infected with B. cepacia complex. A false negative identification, which is most likely to occur if inappropriate culture media are being used is also problematic. It will expose the non-infected CF population to this potentially transmissible organism.
The development of accurate molecular diagnostic techniques has been one of the keys to correct identification and effective infection control measures. Various approaches to molecular detection and identification have been described. The recA PCR is the most sensitive and specific identification. 14, 15 More complex methods such as pulse field gel electrophoresis (PFGE) or restriction fragment length polymorphisms (RFLP) are needed for epidemiological studies to establish the clonal nature of organisms. [16] [17] [18] If an organism is identified as a possible B. cepacia complex the patient should be isolated and the diagnosis confirmed by molecular methods. A number of laboratories in the UK, Europe and North America offer such a service.
Acquisition of B. cepacia complex organisms
B. cepacia complex organisms may be transmitted from patient to patient and may also be acquired from the environment. B. cenocepacia has been identified in the environment but it is likely that most infections are acquired by cross infection between patients. 7, 19 In contrast B. multivorans, vietamiensis and most of the other sub-species are more frequently found to be unique strains in patients and are therefore more likely acquired directly from the environment. 20
Clinical impact of B. cepacia complex
The prognosis of patients infected with B. cepacia complex organisms is considerably worse than patients with CF infected with P. aeruginosa. However this predominantly reflects the effect of B. cenocepacia. A number of studies now suggest that B. multivorans infection behaves more like P. aeruginosa than B. cenocepacia in terms of impact on lung function and survival. The rate of decline of FEV 1 , BMI and the five-year, survival is similar in B. multivorans patients to those with P. aeruginosa infection. 6 In contrast, B. cenocepacia is associated with a rapid deterioration and early death in up to one third of patients who acquire the organism ('cepacia syndrome'), and a more rapid deterioration in lung function to those with P. aeruginosain a further group. 6, 21 However, there are also a subset of patients with B. cenocepacia complex who remain well and stable despite chronic infection with this organism. 22 The reasons for these differences are not clear though may relate to the impact of modifier genes which determine responses to infection or modulate inflammation.
'Cepacia syndrome'
This term relates to patients who acquire a cepacia complex organism and deteriorate rapidly. 5, 6, 21 It is most commonly associated with B. cenocepacia of the subgroup A, and Electrophoresis type 12 (ET12). It may however occasionally occur with B. multivorans infection. 5 It is usually associated with clinical signs of sepsis, weight loss and a sustained acute phase response and sometimes septicaemia. The chest radiograph shows progressive infiltrates. All of this occurs despite aggressive anti-pseudomonal treatment. The progression to early death can occur in a few weeks despite antibiotics, anti-inflammatory treatment, aggressive airways clearance and physiological support for respiratory failure and under-nutrition. Occasionally such patients stabilize for a time and there is some anecdotal evidence that additional use of immuno-suppressive agents such as cyclosporin may be of modest benefit in halting progression. Overall, the mortality is very high in patients developing this syndrome. The 'cepacia syndrome' can develop soon after infection with this organism but may also develop in previous stable patients who are chronically infected. It may be precipitated by incidental events such as acute viral infections.
Chronic infection with B. cepacia complex
For those patients who do not succumb to an acute 'cepacia syndrome', subsequent prognosis is still less good. This particularly applies to patients with Burkholderia cenocepacia. Most of the data available on such patients relates to those infected with a common epidemic strain in Canada and the UK, the Electrophoresis type 12 strain. 5, 6 The strain seems to be the most transmissible and also most virulent strain in the complex. As noted in the previous article it is associated with the B. cepacia epidemic strain marker.
In those centres such as Toronto, Edinburgh, Manchester, Birmingham and Belfast where epidemics have occurred, even those who do not succumb to cepacia syndrome have a more rapid decline in FEV 1 compared to matched patients with chronic P. aeruginosa infection. This is associated with reduced survival. 1, 5, 6 Rather surprisingly, in studies examining airway inflammation in patients with CF when stable or during inflammatory exacerbations, markers of inflammation in patients with B. cenocepacia are similar to those with P. aeruginosa . This may be due to selection bias as these represent those who have survived medium to long-term with the organism and may have a less aggressive inflammatory response. Infection with B. multivorans is also associated with similar requirements for IV antibiotics compared to P. aeruginosa infected patients. In general, the decline in lung function in patients with B. multivorans infection parallel those with P. aeruginosaand are significantly better than patients affected with B. cenocepacia.
Acute exacerbations
Patients with B. cepacia complex have a similar range of co-infecting organisms to those with P. aeruginosa and the response to antibiotics during infective exacerbations is similar. 24 The latter is quite surprising as in vitro testing of sensitivities to anti-pseudomonal antibiotics usually demonstrates almost complete resistance of B. cepacia complex organisms. 24 The routine methods used in laboratories such as disc testing do not accurately reflect the minimal inimatory concentrations (MIC) nor do they reflect the likely effect of synergistic or antagonist combinations. Studies which have investigated synergy testing indicate that combinations including Meropenem, Ceftazidime, Aminoglycosides, Chloramphenicol, Tetracycline and Co-trimoxazole are likely to be useful. 25 Care however, needs to taken to ensure antagonistic combinations are not used. Synergy testing is not routinely available in microbiology laboratories and arrangements are required with specialist laboratories for this service.
The precise choice of IV antibiotics used doing a pulmonary exacerbation is usually based on an empirical decision. Ceftazidime and Tobramycin are a reasonable starting point. Failure to respond to this might suggest a change to Meropenem and/or the addition of Doxycycline, Chloramphenicol or Co-trimoxazole. 26 Compared to patients with P. aeruginosa, patients with B. cepacia complex improve in a similar way in terms of lung function and inflammatory markers. In some situations a triple combination of antibiotics can be helpful. This can be two intravenous and an oral combination.
Lung transplantation
Infection with B. cenocepacia is a relative contra-indication to lung transplantation. The outcomes in such patients are significantly worse than for patients with P. aeruginosa. Around 3% one year survival is reported for B. cepacia complex compared to 70% for those with P. aeruginosa. 27 Complications are mostly related to systemic spread on B. cenocepacia with metastatic abscess formation. Aggressive antibiotic treatment and careful management of immuno-suppression can reduce the impact of this though prognosis remains poor. Some centres now do not transplant patients with B. cepacia complex organisms while others consider it a relative contra indication and make an assessment with other problematic relative contra indications such as low body mass index, presence of diabetes or cystic fibrosis related bone disease. The patients with cystic fibrosis who have other members of the B. cepacia complex such as the B. multivorans or B. vietnamiensis seem to tolerate transplantation as well as patients with P. aeruginosa. 28, 29 These patients with these species of the B. cepacia complex therefore should not be considered as a contra indication to transplantation.
B. cepacia complex and infection control
The principles for infection control for B. cepacia patients are now well established and details can be found in excellent publications from the Cystic Fibrosis Trust (UK) and CF Foundation (USA). 30, 31 Patients with B. cepacia complex should not mix in hospital or social environments with other patients with cystic fibrosis. In addition the greater transmissibility and virulence of B. cenocepacia means that this group should not mix with patients who have infection with B. multivorans or other organisms from the B. cepacia complex. B. cenocepacia has been shown to displace B. multivorans as the predominant infecting organism. Whether patients with B. multivorans should be permitted to mix is unclear. The evidence is that mostly patients carry unique strains, though some centres have demonstrated cross-infection. Until there is evidence to the contrary patients with B. multivorans should be kept separate from each other and all other patients with CF.
All patients with CF should be managed in single rooms and not enter each others rooms. They should not share any equipment, eating utensils or have any close physical contact. Transmission of micro-organisms by hand contact or aerosol can occur and people with CF should probably stay at least one metre from each other when having a conversation. These restrictions should be applied universally including between patients with B. cepacia complex organisms. Careful infection control policies and obsessional adherence to general hygiene by patient's healthcare workers and families can very significantly reduce the frequency of patient to patient spread of B. cepacia complex.
B. cepacia complex (probably B. cenocepacia) has been demonstrated to spread from patients with CF to other patients with bronchiectasis. In the two case reports, however, it is conceivable that these patients may have had atypical CF as the CF genetics were not reported.
Psychosocial implications
Acquiring B. cepacia complex can be a very isolating experience for people with CF. They may loose many friends and have to be transferred to a separate care arrangement with different inpatient facilities, clinic times and so on. The epidemics seen in the 1990s are unlikely to be repeated because of better identification and infection control. Most cases will be sporadic. Newly infected patients may be one of very few patients with B. cepacia complex in the CF Centre and have little contact with any other patients with CF. They are barred from any social contact at CF meetings arranged for patients or parents with CF. Some have described being ostracized and considered as 'microbiological lepers' within the CF community. It is clearly important for healthcare professionals to do what they can to overcome any sense of discrimination and to provide best care possible for patients with B. cepacia complex infection.
B. cepacia complex infection outside of CF

Hospital infections
Organisms from B. cepacia complex have been described as causing infection in numerous situations Practical Management of Cystic Fibrosis JS Elborn within hospitals. A large fatal outbreak has been described in an intensive care unit, indicating that this organism can cause infection when primary host defences are compromised. 32 It has also been described causing wound infection and infection in burns. One of the most common situations where it has caused infection is following contamination of inhaled and intravenous solutions. 33 This can result in airways infection or systemic sepsis.
Environmental uses of B. cepacia complex
Organisms from the B. cepacia complex have been used in a number of environmental situations. 34 It has been described as a plant pathogen but also can be used helpfully as a growth promoter and an antifungal. In addition, because of its large genome and ability to use a wide range of carbon sources, it is useful as a bio-remediation organism.
Conclusion
B. cepacia complex infection has been one of the major challenges for the CF community over the past 20 years. Many young people have died prematurely because of this infection (particularly B. cenocepacia). It has changed the environment in which we manage CF patients from a highly social and interactive community to a culture where patients and healthcare professionals need to be careful about hospital and social contact because of cross-infection of organisms. The lessons learned from B. cepacia complex have indicated that there are some infection control issues related to infection with P. aeruginosa, though the combination of high transmissibility and virulence seen in B. cenocepacia is not mirrored in any of the clonally P. aeruginosa outbreaks described in the UK or Australia. However, with emerging multi-resistant organisms such as Stenotrophomonas maltophilia and Achromobacter xyloxidans it is clearly important that we apply a high standard of infection control and personal hygiene measures to limit the cross-infection of any organism between patients with CF.
